The response varied among cell lines, indicating that the combination of treatment with platinum agents and CHD4 suppression was a more promising therapeutic strategy for ovarian cancer than CHD4 inhibition alone (S6 Fig). The gene discussed is CHD4; the disease is ovarian carcinoma.